Tempus buys out cancer genomics partner Personalis in $1.5 billion deal

fiercehealthcare - Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology.

AI Summary: Tempus is acquiring cancer-genomics company Personalis for roughly $1.5 billion to expand its testing and genomic-service footprint, betting bigger on integrated sequencing and AI-driven oncology diagnostics. The move accelerates Tempus’s push to scale tumor profiling and clinical assays nationwide — and yes, expect louder claims about “transforming cancer care.”